Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials

Yu, Yong; Xu, Xun; Du, Ziyan; Shi, Minhua

doi:10.1007/s00280-012-1833-y

Cited by 12 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of the association between dose of thalidomide and effect, when Hoang et al . [24] increased the dose from 100 mg/day up to 1000 mg/day it did not seem more effective, which was consistent with other studies investigating the dose response relationship in multiple myeloma [31] and small-cell lung cancer [32, 33]. Regarding grade 3–4 toxicity data, our pooled analysis showed that the addition of thalidomide to chemotherapy or chemo-radiotherapy did not increase bone marrow toxicity such as leucopenia or neutropenia but induced a higher rate of grade 3 or greater non-hematologic toxicities including dizziness, constipation, rash and thromboembolic events.…”

Section: Discussionsupporting

confidence: 87%

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

Liu¹,

He²,

Ding³

et al. 2014

View full text Add to dashboard Cite

Several randomized controlled clinical trials have compared therapy with or without thalidomide in the treatment of advanced non-small cell lung cancer (NSCLC). However, these studies did not produce consistent results. We carried out a meta-analysis to determine the efficacy and safety of thalidomide-based therapy in patients with advanced NSCLC. For this meta-analysis, we selected randomized clinical trials that compared thalidomide in combination with other therapy or other therapy alone in patients with advanced NSCLC. The outcomes included median overall survival (OS), one- and two-year survival, tumor response, and toxicities. Hazard ratios (HRs) or risk ratios (RRs) were reported with 95% confidence intervals (CIs). A total of 5 eligible trials were included for the meta-analysis, with 729 patients in the thalidomide group and 711 patients in the control group. Compared with non-thalidomide-based therapy, patients receiving thalidomide plus other therapy did not differ significantly in terms of one- and two-year survival or tumor response (RR = 1.32, 95% CI: 0.66–2.63, p = 0.43; RR = 1.22, 95% CI: 0.48–3.11, p = 0.68; RR = 1.05, 95% CI: 0.92–1.19, p = 0.51, respectively). However, thalidomide-based therapy induced more grade 3–4 dizziness and constipation (RR = 2.05, 95% CI: 1.10–3.81, p = 0.02; RR = 4.78, 95% CI: 1.84–12.38, p = 0.001, respectively). The addition of thalidomide to other therapy did not improve survival and tumor response in patients with advanced NSCLC, and thalidomide-based therapy was associated with more grade 3/4 dizziness and constipation.

show abstract

Section: Discussionsupporting

confidence: 87%

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

Liu¹,

He²,

Ding³

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Non small cell lung cancer (NSCLC) is the leading cause of cancerrelated deaths worldwide and although several active anticancer agents are available, platinum-based chemotherapy is still the standard first-line therapy for patients with metastatic or recurrent disease, achieving better response and progression free survival than non platinum-containing regimens [1].…”

Section: Introductionmentioning

confidence: 99%

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Santelmo¹,

Ravaioli²,

Barzotti³

et al. 2013

Lung Cancer

View full text Add to dashboard Cite

“…Accordingly, the efficacy and safety of taxanes in combination with other third-generation chemotherapy agents such as gemcitabine and vinorelbine have also been assessed [31][32][33][34][35] .…”

Section: Taxanes In Combination With Other Thirdgeneration Chemotheramentioning

confidence: 99%

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

View full text Add to dashboard Cite

standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .Recently, nab-paclitaxel, a 130-nm albuminbound ("nab") form of paclitaxel designed to use endogenous albumin pathways to increase intratumoural concentrations of the active drug, demonstrated improved antitumour activity and tolerability compared with sb-paclitaxel when both were used in combination with carboplatin in the first-line treatment of patients with advanced nsclc 12 . Based on the results of a phase iii trial, nab-paclitaxel in combination with carboplatin was approved in 2012 as first-line therapy for the treatment of locally advanced or metastatic nsclc in patients who are not candidates for curative surgery or radiation therapy 12,13 . The present review summarizes the clinical experience to date with taxanes in the first-line treatment of nsclc. DISCUSSION Taxane-Platinum CombinationsIn landmark nsclc studies, overall response rates (orrs) were higher with taxane-platinum combinations than with other chemotherapy regimens ( Table i). Historically, sb-paclitaxel given in combination with carboplatin or cisplatin demonstrated a median overall survival (os) of 7.7-10 months and an orr of 17%-41% [7][8][9]11,14,[16][17][18]22 . ABSTRACTBased on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxelcarboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

show abstract

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials

Abstract: GD acquired similar survival with platinum-based regimens in first-line treatment of advanced NSCLC. Platinum-based regimens had an advantage in TTP and ORR with more grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia compared with GD.

Cited by 12 publications

References 24 publications

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About